WASHINGTON, D.C. (October 26, 2017) – Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen J. Ubl issued the following statement:
“We commend the Trump Administration for its leadership in tackling the opioid and heroin addiction crisis. We agree that this is a nationwide public health emergency and believe today’s announcement will provide the federal government with more tools and resources to end a tragic epidemic that is being deeply felt by individuals, families and communities across the country.
“This problem is too complex for any single person or policy to solve alone, which is why we have been working closely with this Administration and other health care leaders to expand our efforts. This includes endorsing the comprehensive approach recommended by the President’s Commission on Combatting Drug Addiction and Opioid Abuse in their interim report. PhRMA also recently announced a new partnership with the National Institutes of Health (NIH) and the National Institute on Drug Abuse (NIDA) to bring the best and brightest researchers from across the industry to develop new addiction and drug overdose treatments, as well as non-opioid alternatives to pain management. And we recently announced the industry’s support for a 7-day script limit on opioids for acute pain as part of a comprehensive set of forward-leaning policy solutions that will be laid out in more detail over the coming weeks.
“America’s biopharmaceutical companies are dedicated to coming to the table with real solutions to improve our nation’s public health. The Administration’s commitment to bringing together the best of both the federal government and the private sector gets us closer to our common goal of ending the growing opioid crisis.”
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $65.5 billion in 2016 alone.